Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact
Authors:
- Cecilia NilssonCNCecilia Nilsson
- Ida JohanssonIJIda Johansson
- Cecilia AhlinCACecilia Ahlin
- Sten ThorstensonSTSten Thorstenson
- Rose-Marie AminiRARose-Marie Amini
- Marit HolmqvistMHMarit Holmqvist
- Leif BergkvistLBLeif Bergkvist
- Ingrid HedenfalkIHIngrid Hedenfalk
- Marie-Louise FjällskogMFMarie-Louise Fjällskog
- 29 August 2012
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 52 (1) , 102-109
Abstract
Background. Male breast cancer (MBC) is an uncommon disease and there is limited information on the prognostic impact of routinely used clinicopathological parameters. Material and methods. In a retrospective setting, we reviewed 197 MBC patients with accessible paraffin-embedded tumor tissue and clinicopathological data. Immunohistochemical (IHC) stainings were performed on tissue microarrays and histological grading on conventional slides. Cox proportional regression models were applied for uni- and multivariate analyses using breast cancer death as the event. Results. Estrogen receptor (ER) and progesterone receptor positivity were demonstrated in 93% and 77% of patients, respectively. Nottingham histologic grade (NHG) III was seen in 41% and HER2 positivity in 11%. Classification into molecular subtypes using IHC markers according to three alternative definitions revealed luminal A and luminal B in 81% vs. 11%; 48% vs. 44% and 41% vs. 42% of cases. Two cases of basal-like were identified, but no cases of HER2-like. Factors associated with an increased risk of breast cancer death were node positivity (HR 4.5; 95% CI 1.8–11.1), tumor size > 20 mm (HR 3.3; 95% CI 1.4–7.9) and ER negativity (HR 10.9; 95% CI 3.2–37.9). No difference in breast cancer death between the luminal subgroups was demonstrated, regardless of definition. Conclusion. MBC tumors were more often of high grade, whereas HER2 overexpression was as frequent as in FBC. Lymph nodes, tumor size and ER status were independent predictors of breast cancer death. The prognostic impact of molecular subtyping in MBC seems to differ from that previously established in FBC.Keywords
This publication has 26 references indexed in Scilit:
- Incidence and Outcome of Male Breast Cancer: An International Population-Based StudyJournal of Clinical Oncology, 2011
- Gene expression profiling in breast cancer: classification, prognostication, and predictionThe Lancet, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Similarities and differences in the characteristics and primary treatment of breast cancer in men and women – a population based study (Sweden)Acta Oncologica, 2011
- Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort studyBreast Cancer Research and Treatment, 2010
- Breast Cancer Subtypes and the Risk of Local and Regional RelapseJournal of Clinical Oncology, 2010
- Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 casesCritical Reviews in Oncology/Hematology, 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- Breast carcinoma in menCancer, 2004
- Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with Treatment and Survival, a Study of 65 CasesLaboratory Investigation, 2002